Figure 4
Exposure of whole blood samples to HIV-1 results in increased surface expression of TF on nonclassic (CD14+CD16++) monocytes, but not on the intermediate (CD14++CD16+ CD14+CD16+) or CD14++CD16− monocytes. Whole blood was obtained from HIV-1–uninfected subjects and exposed to LPS (50 ng/mL), imiquimod (5 μg/mL), single-stranded PolyU complexed with the cationic lipid LyovecR (ssPolyU; 10 μg/mL), or AT-2–inactivated HIV-1 (X4 or R5 tropic, 150 ng/mL) for 3 hours. Surface expression of TF was measured on monocyte subsets by flow cytometry. Exposure to LPS resulted in a significant increase in TF on all monocyte subsets, but exposure to imiquimod, ssPolyU, or HIV-1 resulted in increased TF expression on only the CD14+CD16++ subset.

Exposure of whole blood samples to HIV-1 results in increased surface expression of TF on nonclassic (CD14+CD16++) monocytes, but not on the intermediate (CD14++CD16+ CD14+CD16+) or CD14++CD16 monocytes. Whole blood was obtained from HIV-1–uninfected subjects and exposed to LPS (50 ng/mL), imiquimod (5 μg/mL), single-stranded PolyU complexed with the cationic lipid LyovecR (ssPolyU; 10 μg/mL), or AT-2–inactivated HIV-1 (X4 or R5 tropic, 150 ng/mL) for 3 hours. Surface expression of TF was measured on monocyte subsets by flow cytometry. Exposure to LPS resulted in a significant increase in TF on all monocyte subsets, but exposure to imiquimod, ssPolyU, or HIV-1 resulted in increased TF expression on only the CD14+CD16++ subset.

Close Modal

or Create an Account

Close Modal
Close Modal